Business Daily Media

Men's Weekly

.

Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture

  • Written by PR Newswire

World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials in Australia

SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients.

Dupuytren's contracture is a debilitating condition characterized by the fibrosis of the fascia between the skin and tendons of the palm due to collagen buildup, causing fingers to become permanently bent and significantly impairing patients' quality of life. Currently, there is no fundamental cure for this condition. Treatments primarily involve surgical interventions like fasciectomy to alleviate symptoms, although non-surgical methods, such as localized injections of collagenase, have shown high patient satisfaction.

It has received IND approval for Phase 1/2 clinical trials from the U.S. FDA and recently completed the Clinical Trial Notification (CTN) process in Australia. The ongoing clinical trial in Australia represents the Phase 1 part of the Phase 1/2 trial, conducted across three hospitals. The trial involves single administrations of four escalating dose levels in patients with Dupuytren's contracture, followed by a four-week evaluation period to assess safety, tolerability, efficacy, pharmacokinetics, and immunogenicity. Connext plans to secure proof-of-concept (PoC) data by mid-next year and determine the optimal dose for Phase 2, with the aim to commence the Phase 2 trial in the latter half of the year.

Connext CEO Woojong Lee remarked, "This first administration marks a significant milestone, offering new hope to patients suffering from Dupuytren's contracture. We are dedicated to developing a safer and more effective treatment to improve their quality of life."

Connext successfully raised a Series B investment at the end of last year and was selected for the Scale-Up TIPS program, enabling the initiation of global clinical trials for Dupuytren's contracture. The company is simultaneously advancing the development of additional indications, including Peyronie's disease and cellulite.

Media Contact:Sangho Lee(Communication)+82-10-8829-4694Sangho.lee@connext.co.kr[1]

References

  1. ^ Sangho.lee@connext.co.kr (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/4471232_AE71232_0

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

Sell by LayBy